Shared and unique mutational gene co-occurrences in cancers

• Verfasst von: Liu, Junqi [VerfasserIn]
• Verfasst von: Zhao, Di [VerfasserIn]
• Verfasst von: Fan, Ruitai [VerfasserIn]
• Titel: Shared and unique mutational gene co-occurrences in cancers
• Verf.angabe: Junqi Liu, Di Zhao, Ruitai Fan
• E-Jahr: 2015
• Jahr: 2 October 2015
• Umfang: 7 S.
• Fussnoten: Gesehen am 17.01.2019 ; Available online 24 August 2015
• Titel Quelle: Enthalten in: Biochemical and biophysical research communications
• Ort Quelle: [Amsterdam] : Elsevier B.V., 1959
• Jahr Quelle: 2015
• Band/Heft Quelle: 465(2015), 4, Seite 777-783
• ISSN Quelle: 1090-2104
• DOI: doi:10.1016/j.bbrc.2015.08.086
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer treatment
• Sach-SW: Gene mutation
• Sach-SW: Mutation frequency
• Sach-SW: Network
• K10plus-PPN: 1586352288

Abstract

Cancers are often associated with mutations in multiple genes; thus, studying the distributions of genes that harbor cancer-promoting mutations in cancer samples and their co-occurrences could provide insights into cancer diagnostics and treatment. Using data from the Catalogue of Somatic Mutations in Cancer (COSMIC), we found that mutated genes in cancer samples followed a power-law distribution. For instance, a few genes were mutated in a large number of samples (designated as high-frequent genes), while a large number of genes were only mutated in a few samples. This power-law distribution can be found in samples of all cancer types as well as individual cancers. In samples where two or more mutated genes are found, the high-frequent genes, i.e., those that were frequently mutated, often did not co-occur with other genes, while the other genes often tended to co-occur. Co-occurrences of mutated genes were often unique to a certain cancer; however, some co-occurrences were shared by multiple cancer types. Our results revealed distinct patterns of high-frequent genes and those that were less-frequently mutated in the cancer samples in co-occurring and anti-co-occurring networks. Our results indicated that distinct treatment strategies should be adopted for cancer patients with known high-frequent gene mutations and those without. The latter might be better treated with a combination of drugs targeting multiple genes. Our results also suggested that possible cross-cancer treatments, i.e., the use of the same drug combinations, may treat cancers of different histological origins.